Carisma Therapeutics INC. (CARM) — SEC Filings

Overview

Carisma Therapeutics INC. (CARM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Carisma Therapeutics Inc. (CARM) reported a significant turnaround in the nine months ended September 30, 2025, achieving a net income of $25.677 million, a substantial improvement from a net loss of $42.842 million in the same period of 2024. This was primarily driven by a surge in collaboration re

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 7 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Carisma Therapeutics INC. is neutral.

Filing Type Overview

Carisma Therapeutics INC. (CARM) has filed 26 8-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 1 10-K/A, 2 10-K, 3 SC 13D/A, 1 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

• 8-K Filing — 8-K · Dec 5, 2025
• Carisma Swings to Profit Amid Wind-Down, Nasdaq Delisting — 10-Q · Nov 12, 2025 Risk: high
  Carisma Therapeutics Inc. (CARM) reported a significant turnaround in the nine months ended September 30, 2025, achieving a net income of $25.677 million, a sub
• Carisma Therapeutics Files 8-K on Officer/Director Changes — 8-K · Oct 15, 2025 Risk: medium
  Carisma Therapeutics Inc. filed an 8-K on October 15, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of c
• Carisma Therapeutics Faces Delisting Notice — 8-K · Oct 9, 2025 Risk: high
  Carisma Therapeutics Inc. filed an 8-K on October 9, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• Carisma Therapeutics Terminates Material Definitive Agreement — 8-K · Sep 18, 2025 Risk: medium
  Carisma Therapeutics Inc. announced on September 16, 2025, the termination of a material definitive agreement. The company, formerly known as Sesen Bio, Inc. an
• Carisma Therapeutics Reports Material Agreements & Control Changes — 8-K · Aug 29, 2025 Risk: medium
  Carisma Therapeutics Inc. filed an 8-K on August 29, 2025, reporting several key events. These include entering into a material definitive agreement, unregister
• Carisma Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Aug 8, 2025 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on August 8, 2025, reporting on a submission of matters to a vote of security holders that occurred on August 5, 2025. Th
• Carisma Merges with OrthoCellix, Pivots to Gene Therapy — 10-Q · Aug 7, 2025 Risk: high
  Carisma Therapeutics Inc. (CARM) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's n
• Carisma Therapeutics Files Proxy Statement — DEFA14A · Jul 31, 2025 Risk: low
  Carisma Therapeutics Inc. filed a Definitive Proxy Statement (DEFA14A) on July 31, 2025. This filing is related to the company's proxy materials and does not in
• Carisma Therapeutics Faces Delisting Concerns — 8-K · Jul 15, 2025 Risk: high
  Carisma Therapeutics Inc. filed an 8-K on July 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event repo
• Carisma Seeks Reverse Stock Split Approval to Boost Share Price — DEF 14A · Jul 7, 2025 Risk: high
  Carisma Therapeutics Inc. (CARM) is holding a Special Meeting on August 5, 2025, to seek stockholder approval for a reverse stock split. The proposed amendment
• Carisma Therapeutics Inc. Files 8-K: Material Agreement — 8-K · Jun 23, 2025 Risk: medium
  On June 22, 2025, Carisma Therapeutics Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial state
• Carisma Therapeutics Files 8-K — 8-K · Jun 12, 2025 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on June 12, 2025, reporting an event that occurred on June 10, 2025. The filing is categorized under 'Other Events' and p
• Carisma Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Carisma Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Sesen Bio, Inc., is involved in pharmaceutical pre
• Carisma Therapeutics Files 2024 10-K Amendment — 10-K/A · Apr 29, 2025 Risk: low
  Carisma Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Sesen Bio
• Carisma Therapeutics Faces Delisting Notice — 8-K · Apr 16, 2025 Risk: high
  Carisma Therapeutics Inc. filed an 8-K on April 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's stock wa
• Carisma Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Carisma Therapeutics Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Sesen Bio
• Carisma Therapeutics Inc. Files 8-K, Details Name Changes — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Carisma Therapeutics Inc. filed an 8-K report. The filing indicates a change in the company's former name from Sesen Bio, Inc. on May 16, 2
• Carisma Therapeutics Faces Delisting Notice — 8-K · Jan 10, 2025 Risk: high
  Carisma Therapeutics Inc. filed an 8-K on January 10, 2025, reporting a notice of delisting or failure to meet continued listing standards as of January 6, 2025
• Carisma Therapeutics Files 8-K: Board, Officer, and Compensation Updates — 8-K · Dec 26, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on December 26, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangeme
• Carisma Therapeutics to be Acquired by 03 Life Sciences — 8-K · Dec 9, 2024 Risk: medium
  Carisma Therapeutics Inc. announced on December 7, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is
• Carisma Therapeutics Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Carisma Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Carisma Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Sesen Bio, Inc., is involved in pharmaceutical
• Carisma Therapeutics Appoints New CMO and Board Member — 8-K · Oct 30, 2024 Risk: medium
  Carisma Therapeutics Inc. announced on October 24, 2024, the appointment of Dr. Steven D. F. R. Kelly as Chief Medical Officer and Dr. David M. Epstein as a new
• Carisma Therapeutics Faces Nasdaq Delisting Warning — 8-K · Oct 11, 2024 Risk: high
  Carisma Therapeutics Inc. announced on October 10, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing r
• Carisma Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial sta
• Carisma Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Carisma Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op
• Carisma Therapeutics Files 8-K — 8-K · Jul 9, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on July 9, 2024, reporting other events and financial statements. The company, formerly known as Sesen Bio, Inc. and Elev
• Carisma Therapeutics Reports Exit Costs — 8-K · Jul 2, 2024 Risk: medium
  Carisma Therapeutics Inc. filed an 8-K on July 2, 2024, reporting costs associated with exit or disposal activities as of June 26, 2024. The filing details the
• Carisma Therapeutics Announces Board Changes — 8-K · Jul 1, 2024 Risk: low
  Carisma Therapeutics Inc. announced on June 26, 2024, the departure of Dr. Steven T. Rosen, a director, and the election of Dr. Jonathan R. Lurie as a new direc
• Carisma Therapeutics Files 8-K: Other Events & Financials — 8-K · Jun 27, 2024 Risk: medium
  On June 27, 2024, Carisma Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
• Carisma Therapeutics Appoints Dr. Steven T. Rosen to Board — 8-K · Jun 14, 2024 Risk: medium
  Carisma Therapeutics Inc. announced on June 13, 2024, the appointment of Dr. Steven T. Rosen as a new member of its Board of Directors. Dr. Rosen brings extensi
• HealthCap VII Amends Carisma Therapeutics Stake — SC 13D/A · May 28, 2024 Risk: medium
  HealthCap VII, L.P. filed an amendment (No. 3) to its Schedule 13D on May 28, 2024, regarding its beneficial ownership of Carisma Therapeutics Inc. The filing i
• Carisma Therapeutics Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhib
• Carisma Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk:
  Carisma Therapeutics Inc. (CARM) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Carisma Therapeutics Inc. filed a 10-Q report for the quarterly pe
• Carisma Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  Carisma Therapeutics Inc. (CARM) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Carisma Therapeut
• Carisma Therapeutics Files 8-K — 8-K · Apr 10, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on April 10, 2024, reporting other events and financial statements. The company, formerly known as Sesen Bio, Inc. and El
• Carisma Therapeutics Files 8-K on Operations — 8-K · Apr 1, 2024 Risk: low
  Carisma Therapeutics Inc. filed an 8-K on April 1, 2024, reporting on its results of operations and financial condition. The filing also includes financial stat
• Carisma Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  Carisma Therapeutics Inc. (CARM) filed a Annual Report (10-K) with the SEC on April 1, 2024. Carisma Therapeutics Inc. filed its 2023 Annual Report on Form 10-K
• SC 13G Filing — SC 13G · Mar 13, 2024
• HealthCap VII Amends Carisma Therapeutics Stake — SC 13D/A · Mar 7, 2024 Risk: medium
  HealthCap VII, L.P. filed an amendment (No. 2) to its Schedule 13D on March 7, 2024, regarding its beneficial ownership of Carisma Therapeutics Inc. The filing
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Longview Innovation Amends Carisma Therapeutics Stake — SC 13G/A · Feb 2, 2024
  Longview Innovation Corp. filed an amended SC 13G/A on February 2, 2024, indicating a change in their beneficial ownership of Carisma Therapeutics Inc. common s
• University of Pennsylvania Amends Carisma Therapeutics Stake — SC 13D/A · Jan 26, 2024
  The Trustees of the University of Pennsylvania filed an amended SC 13D/A on January 26, 2024, regarding their ownership in Carisma Therapeutics Inc. This amendm

Risk Profile

Risk Assessment: Of CARM's 38 recent filings, 8 were flagged as high-risk, 16 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Carisma Therapeutics INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $48,979,000
• Net Income: $25,677,000
• EPS: $0.61
• Debt-to-Equity: N/A
• Cash Position: $2,777,000
• Operating Margin: 58.6%
• Total Assets: $6,554,000
• Total Debt: $7,421,000

Key Executives

• Board of Directors
• Dr. Steven D. F. R. Kelly
• Dr. David M. Epstein
• Dr. Steven T. Rosen
• Dr. Jonathan R. Lurie
• Steven Kelly

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and collaborations for funding and market access. Recent trends show increased consolidation and a focus on pipeline efficiency, with companies shedding non-core assets or pivoting to more promising therapeutic areas.

Top Tags

financials (6) · delisting (5) · amendment (5) · pharmaceuticals (5) · listing-standards (4) · 8-K (4) · 10-Q (4) · Biotechnology (3) · corporate-governance (3) · regulatory (3)

Key Numbers

• Net Income: $25.677M — Nine months ended Sept 30, 2025, a swing from -$42.842M loss in 2024.
• Collaboration Revenues: $48.979M — Nine months ended Sept 30, 2025, up from $15.979M in 2024.
• Research and Development Expenses: $11.777M — Nine months ended Sept 30, 2025, down from $44.095M in 2024.
• Cash and Cash Equivalents: $2.777M — As of Sept 30, 2025, down from $17.909M at Dec 31, 2024.
• Workforce Reduction: 84% — 37 full-time employees terminated as part of the March 2025 cash preservation plan.
• Termination Fee Receivable: $1.3M — Owed by OrthoCellix for the failed merger, currently unpaid.
• Nasdaq Delisting Date: October 13, 2025 — Common stock suspended from Nasdaq and moved to OTCID.
• Workforce Reduction Costs: $4.2M — Incurred during the nine months ended September 30, 2025.
• Revenue: $0 — for the three and six months ended June 30, 2025, indicating pre-commercial stage
• Merger Date: 2025-06-22 — Carisma Therapeutics Inc. merged with OrthoCellix Inc.
• Private Placement Date: 2025-08-01 — Carisma entered into a private placement with Ocugen
• Minimum Reverse Stock Split Ratio: 1-for-10 — Proposed minimum ratio for Carisma's common stock split
• Maximum Reverse Stock Split Ratio: 1-for-50 — Proposed maximum ratio for Carisma's common stock split
• Special Meeting Date: August 5, 2025 — Date stockholders will vote on the reverse stock split
• Special Meeting Time: 10:00 a.m. Eastern Time — Start time for Carisma's virtual stockholder meeting

Related Companies

OCGN · CRIS

Frequently Asked Questions